Cargando…

Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration

While new vaccines for SARS-CoV-2 are authorized based on neutralizing antibody (nAb) titer against emerging variants of concern, an analogous pathway does not exist for preventative monoclonal antibodies. In this work, nAb titers were assessed as correlates of protection against COVID-19 in the cas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Follmann, Dean, O’Brien, Meagan P., Fintzi, Jonathan, Fay, Michael P., Montefiori, David, Mateja, Allyson, Herman, Gary A., Hooper, Andrea T., Turner, Kenneth C., Chan, Kuo- Chen, Forleo-Neto, Eduardo, Isa, Flonza, Baden, Lindsey R., El Sahly, Hana M., Janes, Holly, Doria-Rose, Nicole, Miller, Jacqueline, Zhou, Honghong, Dang, Weiping, Benkeser, David, Fong, Youyi, Gilbert, Peter B., Marovich, Mary, Cohen, Myron S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10276829/ https://www.ncbi.nlm.nih.gov/pubmed/37330602 http://dx.doi.org/10.1038/s41467-023-39292-w

Ejemplares similares

1939. Who to Boost When: An Analysis of Dosing Interval and Age on COVID-19 Outcomes in the COVE Trial During the Delta and Omicron Waves
por: Follmann, Dean, et al.
Publicado: (2023)

Assessing Durability of Vaccine Effect Following Blinded Crossover in COVID-19 Vaccine Efficacy Trials
por: Follmann, Dean, et al.
Publicado: (2020)

Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 Trial
por: Huang, Ying, et al.
Publicado: (2023)

Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial
por: Benkeser, David, et al.
Publicado: (2023)

Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19
por: O’Brien, Meagan P., et al.
Publicado: (2021)

Subcutaneous REGEN-COV Antibody Combination for Covid-19 Prevention
por: O’Brien, Meagan P., et al.
Publicado: (2021)

A Prospective Study of Key Correlates for Household Transmission of Severe Acute Respiratory Syndrome Coronavirus 2
por: Brown, Elizabeth R, et al.
Publicado: (2023)

COVID-19 prevention with subcutaneous administration of the monoclonal antibodies casirivimab and imdevimab: Subgroup analysis in participants with cardiovascular disease and diabetes
por: O'Brien, Meagan P., et al.
Publicado: (2021)

Subcutaneous REGEN-COV Antibody Combination in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial
por: O’Brien, Meagan P., et al.
Publicado: (2021)

SnapShot: SARS-CoV-2 antibodies
por: Montefiori, David C., et al.
Publicado: (2021)

Broadly neutralizing monoclonal antibodies for HIV prevention
por: Miner, Maurine D., et al.
Publicado: (2021)

Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes
por: Halstead, Scott B, et al.
Publicado: (2010)

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
por: Baden, Lindsey R., et al.
Publicado: (2020)

Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial
por: Herman, Gary A, et al.
Publicado: (2022)

Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge
por: Baden, Lindsey R., et al.
Publicado: (2021)

Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial
por: Gilbert, Peter B., et al.
Publicado: (2021)

Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
por: Gilbert, Peter B., et al.
Publicado: (2021)

Application of the SLAPNAP statistical learning tool to broadly neutralizing antibody HIV prevention research
por: Williamson, Brian D., et al.
Publicado: (2023)

Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19
por: Chalkias, Spyros, et al.
Publicado: (2023)

Profiles of Human Serum Antibody Responses Elicited by Three Leading HIV Vaccines Focusing on the Induction of Env-Specific Antibodies
por: Vaine, Michael, et al.
Publicado: (2010)

Antibody-Dependent Cellular Cytotoxicity (ADCC)-Mediating Antibodies Constrain Neutralizing Antibody Escape Pathway
por: Mielke, Dieter, et al.
Publicado: (2019)

Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine Trials
por: Lora, Alfredo J. Mena, et al.
Publicado: (2023)

Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial
por: Chalkias, Spyros, et al.
Publicado: (2022)

Dose–response curve slope helps predict therapeutic potency and breadth of HIV broadly neutralizing antibodies
por: Webb, Nicholas E., et al.
Publicado: (2015)

Implementation of a three-tiered approach to identify and characterize anti-drug antibodies raised against HIV-specific broadly neutralizing antibodies
por: Bharadwaj, Pranay, et al.
Publicado: (2020)

A novel rabbit monoclonal antibody platform to dissect the diverse repertoire of antibody epitopes for HIV-1 Env immunogen design
por: Chen, Y, et al.
Publicado: (2012)

Antibody Targeting of Eph Receptors in Cancer
por: Janes, Peter W., et al.
Publicado: (2020)

Genetic Signatures in the Envelope Glycoproteins of HIV-1 that Associate with Broadly Neutralizing Antibodies
por: Gnanakaran, S., et al.
Publicado: (2010)

Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial
por: El Sahly, Hana M, et al.
Publicado: (2022)

Monoclonal Antibodies to Disrupt Progression of Early Covid-19 Infection
por: Cohen, Myron S.
Publicado: (2021)

Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
por: El Sahly, Hana M., et al.
Publicado: (2021)

1886. N(1),N(12)-Diacetylspermine as Potential Urinary Biomarker to Monitor Treatment Response and Bacterial Load in Pulmonary Tuberculosis
por: Xia, Qianjing (Jenny), et al.
Publicado: (2019)

Effectiveness of Casirivimab and Imdevimab Antibody Combination in Immunocompromised Hospitalized Patients With Coronavirus Disease 2019: A Post Hoc Analysis in a Phase 1/2/3 Double–Blind Trial
por: Somersan-Karakaya, Selin, et al.
Publicado: (2023)

Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant
por: Lyke, Kirsten E., et al.
Publicado: (2022)

Pharmacokinetics and Immunogenicity of Broadly Neutralizing HIV Monoclonal Antibodies in Macaques
por: Rosenberg, Yvonne, et al.
Publicado: (2015)

Protective Effect of Vaccine Promoted Neutralizing Antibodies against the Intracellular Pathogen Chlamydia trachomatis
por: Olsen, Anja Weinreich, et al.
Publicado: (2017)

Antibody‐virus co‐evolution in HIV infection: paths for HIV vaccine development
por: Bonsignori, Mattia, et al.
Publicado: (2017)

Characterization of a Large Panel of Rabbit Monoclonal Antibodies against HIV-1 gp120 and Isolation of Novel Neutralizing Antibodies against the V3 Loop
por: Qin, Yali, et al.
Publicado: (2015)

A flow cytometry‐based assay to determine the phagocytic activity of both clinical and nonclinical antibody samples against Chlamydia trachomatis
por: Grasse, Marco, et al.
Publicado: (2018)

Insensitivity of Paediatric HIV-1 Subtype C Viruses to Broadly Neutralising Monoclonal Antibodies Raised against Subtype B
por: Gray, Elin Solomonovna, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_ts5fqgm6l4qqn1bosakc7lospf